Hazard Ratio

Type: Keyphrase
Name: Hazard Ratio
First reported 5 hours ago - Updated 2 hours ago - 1 reports

Update: Exelixis COMET-1 Trial Fails: The Impact To My Bull Thesis

Summary The final analysis of its COMET-1 phase 3 pivotal trial of cabozantinib (Cometriq) in men with metastatic castration-resistant prostate cancer has failed. The trial's data release was anticipated in my original article as a potential catalyst ... [Published Seeking Alpha - 5 hours ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Remote Monitoring & ICDs: Slow Uptake Despite Benefits

Remote monitoring of implantable cardioverter-defibrillators (ICDs) and pacemakers shows marked improvement in patient outcomes, if onlypatients and providers would use it.Remote monitoring has progressed from requiring patients to call a center every ... [Published Cardiovascular Business - 3 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer

AUSTIN, Texas , Sept. 2, 2014 /PRNewswire/ -- XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix™.Xilonix, a True Human™ monoclonal antibody therapy, is being evaluated ... [Published SearchBug - 5 hours ago]
First reported Aug 31 2014 - Updated Sep 01 2014 - 1 reports

Ivabradine makes no dent on mortality in patents with stable CAD

Heart patients taking ivabradine did not experience a higher survival rate over placebo in a trial published online Aug. 31 in the New England Journal of Medicine and presented at the 2014 European Society of Cardiology Congress in Barcelona.Ivabradine, ... [Published Cardiovascular Business - Aug 31 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Eisai submits applications for approval of thyroid cancer drug to FDA and EMA

Compared to placebo, lenvatinib achieved a statistically significant improvement (Hazard Ratio (HR) 0.21, p0.0001) in progression free survival (PFS), which was the primary objective of the study. The most common lenvatinib treatment-related adverse events ... [Published Individual.com - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Tea helps reduce non-cardiovascular death risk by almost a quarter

Washington, Sep 01 (ANI): A new study has revealed that drinking tea helps in curbing non-cardiovascular mortality by 24 percent.Professor Nicolas Danchin said that drinking tea would be a better choice than coffee, although both are important for the ... [Published TruthDive - Sep 01 2014]
Entities: Coffee, Mortality, Risk, Smoking
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B-A Nationwide Cohort Study

"In conclusion, nucleos(t)ide analogue use is associated with reduced risk of HCC in CHB patients. Age, sex, liver cirrhosis, and diabetes mellitus modify this association. More studies are needed to explore the wider use of nucleos(t)ide analogues for ... [Published National AIDS Treatment Advocacy Project - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Long-Term Prognosis of Patients with Carbon Monoxide Poisoning: A Nationwide Cohort Study

by Chien-Cheng Huang, Min-Hsien Chung, Shih-Feng Weng, Chih-Chiang Chien, Shio-Jean Lin, Hung-Jung Lin, How-Ran Guo, Shih-Bin Su, Chien-Chin Hsu, Chi-Wen JuanBackgroundCarbon monoxide poisoning (COP) often produces severe complications and can be fatal. ... [Published Plosone.org - Aug 28 2014]
First reported Aug 22 2014 - Updated Aug 23 2014 - 1 reports

Deletion predicts survival in advanced non-small cell lung cancer

PUBLIC RELEASE DATE: 22-Aug-2014DENVER – Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ... [Published EurekAlert! - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Treatments for Idiopathic Pulmonary Fibrosis

Dr. King and colleagues reply: Ohkubo and colleagues inquire about acute exacerbations of idiopathic pulmonary fibrosis. In the ASCEND trial, we did not evaluate acute exacerbations because of the challenges associated with its diagnosis 1 and the low ... [Published New England Journal of Medicine - Aug 21 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 2 reports

Optimal starting point for antiretroviral HIV treatment in a town in Cameroon: a randomised ...

Optimal starting point for antiretroviral treatment (ART) has been uncertain.Methods: Parallel group, single blind, randomised controlled study of adult HIV positive patients consulting at the Protestant Hospital, Ngaoundere, Cameroon in 2007-8. Simple ... [Published 7thSpace - Aug 10 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

An approach to trial design and analysis in the era of non-proportional hazards of the treatment ...

Most randomized controlled trials with a time-to-event outcome are designed and analysed under theproportional hazards assumption, with a target hazard ratio for the treatment effect in mind. However,the hazards may be non-proportional.We address how ... [Published 7thSpace - Aug 07 2014]


...that has a pCR does better than a patient who does not have a pCR is absolutely true in the majority of subtypes of breast cancer," Mamounas said. "When it comes to HER2-positive patients, triple-negative patients, or high-proliferative ER-positive patients, clearly those who achieve a pCR do significantly better than those who not, that much is clear from this analysis and any other study that has been published on that subject."
...E Clarson, MBChB, from the ResearchResearch Institute for Primary Care & Health Sciences at Keele University in the United Kingdom, and colleagues. "Although gout is traditionally thought of as an intermittent inflammatory condition, recent ultrasound studies have identified persistent subclinical inflammation in the intercritical period between acute attacks. It has been hypothesised that the combination of persistent inflammation and hyperuricaemia may potentiate or synergise CHD development."
"If the data is sound, the stock could skyrocket. But if it comes up short, shares will get crushed. With cash being such an issue, Exelixis really does need some of the Phase 3 trials to have excellent outcomes. The biggest catalyst will be the final Phase 3 COMET-1 data."
...in atrial fibrillation: What really matters? " one of the presenters, Dr Tze-Fan Chao (Taipei Veterans General Hospital, Taiwan), insisted, "There's nothing low risk about 3.3% per"

More Content

All (334) | News (302) | Reports (0) | Blogs (32) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Subtype, pCR Predict Locoregional Recurrence Fo... [Published OncLive - 1 hour ago]
Update: Exelixis COMET-1 Trial Fails: The Impac... [Published BioPortfolio - 2 hours ago]
Cabozantinib (Cometriq) Fails to Meet Primary E... [Published PT Community - 3 hours ago]
Preventing Acute Malnutrition among Young Child... [Published PLoS medicine - 3 hours ago]
Remote Monitoring & ICDs: Slow Uptake Despite B... [Published Cardiovascular Business - 3 hours ago]
Gout Linked to Increased Vascular Disease Risk [Published WebMD - 4 hours ago]
Correspondence: gender and outcome from acute m... [Published British Journal of Cardiology - 4 hours ago]
Update: Exelixis COMET-1 Trial Fails: The Impac... [Published Seeking Alpha - 5 hours ago]
Not All CHA2DS2-VASc 1s Are Created Equal: No K... [Published American Journal of Public Health - 5 hours ago]
XBiotech Halts Study, Reports Positive Phase II... [Published SearchBug - 5 hours ago]
Why Exelixis Inc. Stock Plunged [Published Nasdaq - 5 hours ago]
Exelixis' CEO Presents at COMET-1 Results Confe... [Published Seeking Alpha - 7 hours ago]
Coffee increases prediabetes risk in susceptibl... [Published EurekAlert! - 11 hours ago]
Celsion Announces Enrollment of First Patient i... [Published Tamar Securities - 11 hours ago]
FFR guided drug-eluting stenting reduces death ... [Published News-Medical.Net - 12 hours ago]
Exelixis, Inc.'s Not So Excellent Prostate Canc... [Published Motley Fool Discussion Boards - 12 hours ago]
Fractional Flow Reserve–Guided PCI for Stable C... [Published New England Journal of Medicine - 15 hours ago]
Outcomes 1 Year after Thrombus Aspiration for M... [Published New England Journal of Medicine - 15 hours ago]
15-PGDH Expression in Normal Mucosa May Be Biom... [Published The ASCO Post - 16 hours ago]
FDA Approves Bevacizumab for Aggressive and Lat... [Published The ASCO Post - 17 hours ago]
Surveillance and Mortality in Esophageal Adenoc... [Published Diabetes Care - 18 hours ago]
Drink tea for longer, healthier life, study shows [Published Malay Mail - 20 hours ago]
Failure of IGF-1R Inhibitor Figitumumab in Adva... [Published The ASCO Post - 20 hours ago]
Phase III Trial of Figitumumab Plus Chemotherap... [Published The ASCO Post - 22 hours ago]
Emerging Approaches in Acute Myeloid Leukemia [Published The ASCO Post - 23 hours ago]
[Comment] Ovarian tissue cryopreservation in ch... [Published Lancet Oncology - 23 hours ago]
[Comment] The ProtecT trial: what can we expect? [Published Lancet Oncology - 23 hours ago]
[Articles] Fertility preservation for girls and... [Published Lancet Oncology - 23 hours ago]
Exelixis Announces Results from the COMET-1 Pha... [Published Town Hall - Sep 01 2014]
Heart failure drug could 'cut deaths by a fifth' [Published Cotswold Journal - Sep 01 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
Study: Use of methylphenidate-based ADHD medica... [Published SharpBrains - Aug 20 2014]
ADHD medication enhances the risk of heart problems in children (Science Nordic): “The risk of developing heart problems is twice as big for children taking medicine for Attention Deficit-Hyperactivity Disorder (ADHD) when compared to children not ...
Evidence and colorectal screening policy: a mis... [Published The Incidental Economist (Posts) - Aug 14 2014]
From JAMA, “ Effect of Flexible Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality “: Importance: Colorectal cancer is a major health burden. Screening is recommended in many countries. Objective: To estimate the effectiveness of ...
Psychiatric problems are more common in MSers [Published Multiple Sclerosis Research - Aug 10 2014]
Brenner P et a. Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study. PLoS One. 2014 Aug 5;9(8):e104165. doi: 10.1371/journal.pone.0104165. eCollection 2014. Background:Psychiatric ...
Takeda Receives Positive CHMP Opinions for Labe... [Published Nycomed News RSS feed - Jul 29 2014]
ZURICH, July 29, 2014 – Takeda Pharmaceuticals International GmbH (“Takeda”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for updates ...
A Biotech Stock Is Up Nearly 300% After Announc... [Published Clusterstock - Jul 23 2014]
Shares of Puma Biotechnology are up 296% right now. On Tuesday evening, the company announced encouraging results from its recent breast cancerdrug  trial. "[A] clinical trial of its experimental drug blocked the return of breast cancer in women ...
1 2 3 4 5 6 7
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.